Study Shows Leqembi Cuts Cognitive Decline by 31%

New data shows Eisai and Biogen's Alzheimer's drug, Leqembi, provides increasing benefits over three years, reducing cognitive decline by 31% compared to untreated patients. The study confirmed no new safety concerns, highlighting Leqembi’s effectiveness and potential for long-term Alzheimer’s management.

Approved last year, Eisai and Biogen's Leqembi initially reduced cognitive decline by 27% after 18 months. New three-year data shows that Leqembi now slows cognitive decline by 31% compared to untreated patients, with continued use enhancing its benefits. The study, covering about 95% of original trial participants, reports no new safety issues beyond the initial six months, where brain swelling and bleeding were primarily observed, according to Christopher van Dyck, Professor of Neuroscience, Yale’s Alzheimer’s Disease Research Unit.

In a separate mid stage study, patients who had a break in treatment showed a return to cognitive decline rates similar to those receiving a placebo. This study also noted a resurgence of Alzheimer's-related biomarkers, such as amyloid plaques, when treatment was discontinued, reports Reuters. 

Leqembi targets protofibrils, toxic precursors to amyloid plaques, and continues to address them even after plaque removal. This method differs from Eli Lilly’s Kisunla, which only targets amyloid plaques and allows treatment to be discontinued once plaques are removed. Kisunla is priced at approximately US$695.65 per vial, totaling around $32,000 for a year of 13 infusions. In contrast, Leqembi costs US$26,500 annually, reports MBN. 

Lynn Kramer, Chief Clinical Officer, Eisai, emphasized the significance of long-term benefits in Alzheimer's treatment. The studies presented at the conference highlight the continued efficacy of Leqembi and its distinct approach compared to other Alzheimer's drugs.